VIVE — Viveve Medical Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.28m
- $6.43m
Annual income statement for Viveve Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.3 | 18.5 | 6.57 | 5.48 | 6.43 |
Cost of Revenue | |||||
Gross Profit | 7.44 | 7.32 | 1.02 | 0.296 | 0.62 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 49 | 63.5 | 44 | 24 | 26.6 |
Operating Profit | -33.7 | -45 | -37.4 | -18.5 | -20.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -37 | -49.3 | -41.9 | -21.5 | -21.8 |
Net Income After Taxes | -37 | -49.3 | -41.9 | -21.5 | -21.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -37 | -50 | -42.5 | -21.9 | -22 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -37 | -50 | -42.9 | -26.1 | -26.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2,112 | -1,609 | -284 | -16.6 | -2.78 |